Key Developments: BioScrip Inc (BIOS.O)
13.48USD
24 May 2013
$-0.12 (-0.88%)
$13.60
$13.58
$13.59
$13.32
256,058
608,804
$14.73
$6.14
Latest Key Developments (Source: Significant Developments)
BioScrip Inc Reaffirms FY 2013 Guidance
BioScrip Inc announced that it reaffirms its initial 2013 revenue target of $830.0 million to $865.0 million and 2013 Adjusted EBITDA target of $67.0 million to $73.0 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $837.7 million for fiscal 2013. Full Article
BioScrip Inc Closes Underwritten Offering Of Common Stock
BioScrip Inc announced that the closing of the underwritten public offering of 14,375,000 shares of its common stock at a public offering price of $12.00 per share, including 3,968,750 shares of common stock offered by certain selling stockholders. Of the 14,375,000 shares offered, an aggregate of 1,875,000 shares of common stock were sold pursuant to the underwriters' option granted by the Company and the selling stockholders. The Company will not receive any proceeds from the sale of shares of common stock by the selling stockholders. After payment of the underwriting discount and estimated offering expenses, the Company received net proceeds of approximately $118.2 million. Jefferies LLC, Morgan Stanley & Co. LLC and SunTrust Robinson Humphrey, Inc. acted as joint book-running managers. Dougherty & Company and Noble Financial Capital Markets acted as co-managers. Full Article
BioScrip Inc Prices Underwritten Offering Of Common Stock
BioScrip Inc announced the pricing of an underwritten offering of 12,500,000 shares of common stock at a price to the public of $12.00 per share, including 3,125,000 shares of common stock offered by certain selling stockholders. The Company will not receive any proceeds from the sale of shares of common stock by the selling stockholders. After payment of the underwriting discount and estimated offering expenses, the Company expects to receive net proceeds of approximately $106.5 million. Jefferies LLC, Morgan Stanley & Co. LLC and SunTrust Robinson Humphrey, Inc., are acting as joint book-running managers. Dougherty & Company and Noble Financial Capital Markets are acting as co-managers. The Company and the selling stockholders have granted the underwriters an option for a period of 30 days to purchase up to an additional 1,875,000 shares of the Company's common stock. Full Article
BioScrip Inc Proposes Public Offering of Common Stock
BioScrip Inc announced it has commenced an underwritten public offering of its common stock. Both the Company and certain selling stockholders will offer shares of the Company's common stock as part of the public offering. BioScrip will not receive any proceeds from the sale of shares of common stock by the selling stockholders. Jefferies LLC, Morgan Stanley & Co. LLC and SunTrust Robinson Humphrey, Inc. are acting as joint book-running managers. Dougherty & Company and Noble Financial Capital Markets are acting as co-managers. The Company and the selling stockholders expect to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering. Full Article
BioScrip Inc Issues FY 2013 Guidance Above Analysts' Estimates
BioScrip Inc announced that for fiscal 2013, it expects revenue to grow by 25% to 30% to a range of $830.0 million to $865.0 million and the Company is initially targeting adjusted EBITDA of $67.0 million to $73.0 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $786 million and EBITDA of $64 million for fiscal 2013. Full Article
BioScrip Inc Closes Acquisition of DaVita HealthCare Partners Inc's Subsidiary HomeChoice Partners Inc
BioScrip Inc announced the February 1, 2013 closing of its previously announced agreement to acquire HomeChoice Partners Inc, provider of alternate-site infusion pharmacy services, for $70.0 million in cash. HomeChoice was a majority-owned subsidiary of DaVita HealthCare Partners Inc. Full Article
BioScrip Inc Enters Into Agreement To Acquire DaVita HealthCare Partners Inc's HomeChoice Partners, Inc.
BioScrip Inc announced that it has entered into a definitive agreement to acquire HomeChoice Partners, Inc. ("HomeChoice"), a provider of alternate-site infusion pharmacy services, for $70.0 million in cash. HomeChoice is a majority-owned subsidiary of DaVita HealthCare Partners Inc. The purchase price is subject to adjustment pursuant to the terms of the agreement including potential additional consideration based on the results of operations. BioScrip also expects to realize the value of a future tax benefit estimated at $3.9 million as a result of the transaction. The transaction is subject to customary closing conditions, including regulatory approval. The company expects the transaction will close in the first quarter of 2013. Full Article
BioScrip Inc Reaffirms FY 2012 Guidance
BioScrip Inc announced that for fiscal 2012, it expects annualized revenue range of $660-$690 million and adjusted EBITDA range of $62-65 million. Full Article
BioScrip Inc Raises FY 2012 Revenue Guidance; Reaffirms FY 2012 EBITDA Guidance
BioScrip Inc announced that for fiscal 2012, it is increasing its target annualized revenue from $600-$620 million to $620-$650 million, and reiterating its annualized Adjusted EBITDA of $62-65 million in the fourth quarter of 2012. As previously disclosed, the Company anticipates certain short-term factors and additional costs during the third quarter of 2012 will impact near term financial results. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $623 million for fiscal 2012. Full Article
Walgreen Co Completes Acquisition Of Certain Assets Of BioScrip's Community Specialty Pharmacies And Centralized Specialty And Mail Service Pharmacy Businesses
Walgreen Co announced that it has completed its acquisition of certain assets of BioScrip, Inc.’s community specialty pharmacies and centralized specialty and mail service pharmacy businesses. The transaction represents a total deal value of approximately $225 million. The acquired community specialty pharmacy business includes a national network with 30 locations in 16 states across the U.S. and the District of Columbia, primarily serving HIV, oncology and transplant patients. Walgreens also acquired certain assets of BioScrip's centralized specialty pharmacy business and traditional mail service pharmacy business that dispenses prescriptions for, among others, drugstore.com, which was acquired by Walgreens in June 2011. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
